BB 3

Drug Profile

BB 3

Alternative Names: BB-3; Refanalin

Latest Information Update: 01 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Angion Biomedica
  • Class Small molecules
  • Mechanism of Action Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal failure
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal failure
  • Phase II Acute kidney injury
  • No development reported Heart failure
  • Discontinued Hepatic fibrosis; Myocardial infarction; Stroke

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Acute kidney injury (Prevention) in USA (IV) (NCT02771509)
  • 01 Jan 2016 Phase-III clinical trials in Renal failure in USA (IV) (NCT02474667)
  • 18 Aug 2015 BB 3 is still in phase II development for Renal failure/delayed graft function in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top